NEW YORK (GenomeWeb News) – Protea Biosciences has licensed technology from Johns Hopkins University that it plans to use to develop tools for improving treatment of myocardial ischemia, the company said today.

The company has licensed technology developed in the lab of Hopkins researcher Jennifer Van Eyk that has been used to identify proteins bound to human serum albumin that are associated with cardiovascular disease.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

American scientists find themselves once again warning the Trump administration not to dismiss science, the New Yorker report.

A new study suggests CRISPR could be used to save coral reefs from dying off, Forbes reports.

Researchers have found that the i-motif shape of DNA previously observed in the lab also exists in human cells, and that it may serve a purpose.

In PNAS this week: a genomic, transcriptomic, and metabolomic analysis of the tea plant, Arabidopsis thaliana's adaptations to specific local environments, and more.